Navigation Links
McMaster study contradicts reports of problems with blood-thinner
Date:8/29/2010

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

After researchers from the United States, France and Germany reported clopidogrel is less effective in some patients, the Food and Drug Administration (FDA) in the United States issued a black box warning to physicians on the drug's package insert.

"(Our findings) add a further layer of complexity to the FDA 'black box' warning and show that reported genetic variants have no effect in certain patient populations," said Dr. Guillaume Par, lead researcher and assistant professor of pathology and molecular medicine at the Michael G. DeGroote School of Medicine.

Clopidogrel is the world's second best-selling prescription drug with global sales of more than $6 billion annually. It is used in 110 countries by millions of people to reduce the risk of heart attack and stroke.

Following the FDA's warning, clopidogrel became the focus of on-going debates within cardiology circles. Some American cardiologists initially called the FDA's actions irresponsible. Others complained they were left without any appropriate direction on how to manage their patients.

About 20 per cent of the population carry the loss-of-function version of the gene involved in the clopidogrel controversy.

To assess the influence genetics might have on patients prescribed clopidogrel, Par and colleagues from McMaster University conducted a genetic sub-study of 6,000 participants from two major clinical trials (CURE and ACTIVE). The CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events) trial of 12,562 patients with acute coronary syndrome in 28 countries found clopidogrel significantly reduces the risk of heart attack stroke and dying. The ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for the Prevention of Vascular Events) tr
'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140
McMaster University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. McMaster researcher leads development of promising drug for inflammation
2. Vaccine has cut child cases of bacterial pneumonia, says study
3. Even Before Recession, 14 Million Kids Underinsured: Study
4. Penn study sheds light on how the brain shifts between sleep/awake states under anesthesia
5. Study Links Gene to Serious Eye Disease
6. Study Suggests Statins Could Help Some With Normal Cholesterol
7. Heart Risks the Same With 2 Diabetes Drugs: Study
8. Mayo researchers develop new laboratory cell lines to study treatment for ATC
9. Herpes Drugs Wont Raise Birth Defect Risk, Study Finds
10. Mumps vaccine coverage should be improved, study finds
11. Study Suggests Link Between Diet Sodas, Preterm Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 The National Association of ... DSL, LSSBB (C), First Sergeant A Co., 15BSB , ... the Year Circle. She is recognized with this prestigious ... nation's leading networking organization exclusively for professional women, boasting ... Chapters. , “I'm pleased to recognize Sergeant Cornett with ...
(Date:6/1/2015)... 01, 2015 Carson Energy also announced ... investors IRA transactions. AdvantaIRA Trust, LLC is the country’s ... ability to fund positions using IRA’s does 2 things:, ... a project, even if there current cash position will ... funding source for Carson and their investors to be ...
(Date:6/1/2015)... 2015 The federal court overseeing hundreds ... the Case Management Order governing case selection for bellwether ... Amended Order which was issued in the U.S. District ... directs the parties to submit a Proposed Case Management ... outlines parameters and the process for selecting AbbVie-only plaintiffs ...
(Date:6/1/2015)... 2015 Atagi Plastic Surgery and Skin ... an Ultherapy® Ultra Treatment Provider by Ulthera, ... Aesthetics is one of only six practices in Colorado ... provider. , Atagi Plastic Surgery and Skin Aesthetics’ ... has led the practice to earn the distinction of ...
(Date:6/1/2015)... 01, 2015 Linda Kincaid, age 67, knew ... irregular heartbeat. At first she thought it was just a ... was much more than that. After going to the doctor, ... she felt afraid about what might happen to her. , ... are diagnosed with valve disease each year. Valve disease involves ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3
... Aurora Health Care ... bi-lateral knee replacement this morning. This first, ... helped to reach thousands of viewers. (Photo: ... the surgery, Aurora caregivers posted updates as "tweets" ...
... say , , THURSDAY, April 16 (HealthDay News) -- The ... blindness-causing macular edema in people with diabetes who have ... About 50 percent of people who have type 1 ... diabetes develop retinopathy, which is damage to the retina ...
... It first began as an idea to fight ... and in fact, Accents in Water remains the only ... today. Then, general public settings like restaurants, office buildings, ... a matter of time before custom interior designers and ...
... on Patients & Businesses Nationwide in Letter to the ... April 16 In a letter sent yesterday, a ... White House Office of Health Reform, the Centers for ... Health and Human Services to review and rescind the ...
... for laboratories, future growthMUNDELEIN, Ill., April 16 ... diagnostic instrument manufacturer and information systems developer, ... with BioReference Laboratories, Inc. BioReference Laboratories, purchases ... of XE-Series Automated Hematology Analyzers, Sysmex SP-1000 ...
... , April 16 The "Help is ... the week of April 20 - April 24 at various ... information on programs that provide prescription medicines for free or ... percent, above the national average of 8.5 percent, the Partnership ...
Cached Medicine News:Health News:Aurora Health Care Twitter-Surgery A Success 2Health News:Drug May Not Help Diabetes-Related Eye Damage 2Health News:Hospital Approved Residential Water Features Kill Harmful Airborne Bacteria 2Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 2Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 3Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 4Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 5Health News:BioReference Laboratories Partners With Sysmex America 2Health News:BioReference Laboratories Partners With Sysmex America 3Health News:Partnership for Prescription Assistance Prepared to Help Indiana Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Indiana Workers Hurt by Recession 3
(Date:6/1/2015)... 1, 2015  Research Solutions, Inc. (OTCQB: RSSS), a pioneer ... (STM) information for life science companies, academic institutions, and ... at the LD Micro Invitational being held on June ... Los Angeles . ... June 3rd at 9:30 a.m. Pacific time, with one-on-one ...
(Date:6/1/2015)... June 1, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic ... public offering of its common stock consisting of 1,475,506 ... to be sold by certain of its stockholders. In ... option to purchase up to an additional 590,202 shares ...
(Date:6/1/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data from its Phase I/II clinical trial of  ... (GBM), the most common and deadly form of ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8
... DIEGO , April 27 CareFusion Corporation (NYSE: CFN ) ... Thursday, May 6 following the close of trading on the New York Stock ... The company will host a webcast and ... ( 5 p.m. Eastern time ) to discuss the results for its third quarter, ...
... , April 27 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... provide a general business overview, as well as to discuss first quarter 2010 ... Eastern Time ( 2:00 p.m. Pacific Time ).  Financial results for the ... day. , , , ...
Cached Medicine Technology:CareFusion Will Host an Earnings Conference Call on May 6 to Discuss the Results for the Third Quarter of Fiscal 2010 2Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast 2
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits....
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... washers available to handle multiple ... assays. Embla 384 Cell washer ... been optimized to avoid cell ... compatible and have been integrated ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: